iCAN IVD predicts treatment outcomes
Colorectal cancer comprises unique tumors, each with specific traits affecting treatment response. In today’s cancer care, oncologists rely on standard approaches like DNA sequencing of biomarkers for treatment decisions.
However, these methods often predict outcomes poorly, resulting in 70% of patients receiving suboptimal care. With iCAN IVD – Oncosyne’s diagnostics platform utilizing patient-derived tumoroids – optimal treatment can be personalized for each patient.
A vital aspect is that iCAN IVD also allows for extended cell culture, facilitating the testing of combination therapies that ultimately are essential to treat and even cure most advanced cancers.
iCAN IVD is under clinical investigation for predictive diagnostics in cancer patients. Presently Oncosyne has completed a clinical pilot study, TargetCRC, in which the technology platform was validated and verified and is currently working on improving iCAN IVD’s clinical feasibility and utility.
If you’re interested in how iCAN IVD can help your organization, contact us.
THE DIAGNOSTICS PROCESS
iCAN IVD – a unique platform for predictive diagnostics
The diagnostic process using iCAN IVD typically takes between two to eight weeks from start to finish, which aligns well with the lead times for cancer surgery and subsequent treatment in the care process. In summary, the process consists of six steps:
- Sampling at the clinic
Oncosyne receives a fresh tumor biopsy or resection.
2-3. Transformation into tumoroids
The sample is processed and transformed into tumoroids that mimic the patient’s tumor and is cultured for one to seven weeks.
4. Drug exposure
The tumoroids are exposed to a panel of drugs over several days, after which they are stained with markers of cell viability and cell death before high-content imaging and computer vision-based image analysis.
5. Analysis
The resulting phenotypic data contain functional and morphological information, establishing which drugs (or combinations of drugs) the patient’s tumor is susceptible to in the panel.
6. Personalized diagnostics report
The results are fed into a multi-parametric nomination algorithm that generates a personalized diagnostic report that the treating physician can use to tailor the most efficient drug regimen for the individual patient.
Oncosyne’s diagnostics platform uses patient-derived tumoroids to identify the best drug treatment for each patient
Contact
For inquiries about our services, send us an email or give us a call.
We look forward to hearing from you.
Email: post@oncosyne.no
Telephone: +47 412 34 614
